The prognosis for patients with systemic lupus erythematosus (SLE) has improved significantly, with 20-year survival now approximately 80% owing partly to effective treatment. SLE treatment has evolved from the use of conventional drugs such as hydroxychloroquine and corticosteroids, nonspecific immunosuppressants including mycophenolate mofetil, to targeting selective components of the immune cascade with a view to increased efficacy, tolerability and safety profile. These novel treatments include B-cell-depleting antibodies and fusion proteins that block the costimulatory pathways of B and T cells. A discussion of these pharmacological options and ongoing research forms the basis of this review.
Allison, A.C. ( 2005) Mechanisms of action of mycophenolate mofetil. Lupus14(Suppl. 1): S2-S8.
2.
Allison, M. ( 2010) PML problems loom for Rituxan. Nat Biotechnol28: 105-106.
3.
American College of Rheumatology (2009) Efficacy and safety of rituximab in subjects with active proliferative lupus nephritis (LN): Results from the randomised, double-blind phase III LUNAR study. ACR/ARHP Annual Scientific Meeting, Philadelphia, PA, Presentation 1149.
4.
Anderka, M.T., Lin, A.E., Abuelo, D.N., Mitchell, A.A. and Rasmussen, S.A.(2009) Reviewing the evidence for mycophenolate mofetil as a new teratogen: case report and review of the literature. Am J Med Genetics A149A: 1241-1248.
5.
Appel, G.B., Contreras, G., Dooley, M.A., Ginzler, E.M., Isenberg, D., Jayne, D. et al. (2009) Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol20: 1103-1112.
6.
Austin, H.A., Klippel, J.H., Balow, J.E., le Riche, N.G., Steinberg, A.D., Plotz, P.H. et al. (1986) Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. N Engl J Med314: 614-619.
7.
Barile-Fabris, L., Ariza-Andraca, R., Olguín-Ortega, L., Jara, L.J., Fraga-Mouret, A., Miranda-Limón, J.M. et al. (2005) Controlled clinical trial of IV cyclophosphamide versus IV methylprednisolone in severe neurological manifestations in systemic lupus erythematosus. Ann Rheum Dis64: 620-625.
8.
Barnes, E.V., Narain, S., Naranjo, A., Shuster, J., Segal, M.S., Sobel, E.S. et al. (2005) High sensitivity C-reactive protein in systemic lupus erythematosus: relation to disease activity, clinical presentation and implications for cardiovascular risk. Lupus14: 576-582.
9.
Bertoli, A. and Alarcón, G. ( 2007) Epidemiology of systemic lupus erythematosus. A Companion to Rheumatology Systemic Lupus Erythematosus, Mosby Elsevier: Philadelphia, PA.
10.
Bessant, R., Hingorani, A., Patel, L., MacGregor, A., Isenberg, D.A. and Rahman, A. ( 2004) Risk of coronary heart disease and stroke in a large British cohort of patients with systemic lupus erythematosus. Rheumatology43: 924-929.
11.
Blumenfeld, Z., Shapiro, D., Shteinberg, M., Avivi, I. and Nahir, M. ( 2000) Preservation of fertility and ovarian function and minimizing gonadotoxicity in young women with systemic lupus erythematosus treated by chemotherapy. Lupus9: 401-405.
12.
Bohm, M., Gaubitz, M., Luger, T.A., Metze, D. and Bonsmann, G. ( 2003) Topical tacrolimus as a therapeutic adjunct in patients with cutaneous lupus erythematosus. Dermatology207: 381-385.
13.
Boumpas, D.T., Austin, H.A., Vaughan, E.M., Yarboro, C.H., Klippel, J.H. and Balow, J.E. ( 1993) Risk for sustained amenorrhea in patients with systemic lupus erythematosus receiving intermittent pulse cyclophosphamide therapy . Ann Intern Med119: 366-369.
14.
Boumpas, D.T., Austin, H.A., Vaughn, E.M., Klippel, J.H., Steinberg, A.D., Yarboro, C.H. et al. (1992) Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet340: 741-745.
15.
Boumpas, D.T., Dimitrios, T., Furie, R., Manzi, S., Illei, G.G., Wallace, D.J. et al. (2003) A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis. Arthritis Rheum48: 719-727.
16.
Boumpas, D.T. and Papadimitraki, E.D. ( 2007) Cytotoxic drug treatment. A Companion to Rheumatology Systemic Lupus Erythematosus, Mosby Elsevier : Philadelphia, PA.
17.
Bruce, I.N., Urowitz, M.B., Gladman, D.D. and Hallett, D.C. ( 1999) Natural history of hypercholesterolemia in systemic lupus erythematosus. J Rheumatol26: 2137-2143.
18.
Buchanan, N.M., Toubi, E., Khamashta, M.A., Lima, F., Kerslake, S. and Hughes, G.R. ( 1996) Hydroxychloroquine and lupus pregnancy: review of a series of 36 cases. Ann Rheum Dis55: 486-488.
19.
Cambridge, G., Isenberg, D.A., Edwards, J.C.W., Leandro, M.J., Migone, T.-S., Teodorescu, M. et al. (2007) B cell depletion therapy in systemic lupus erythematosus: relationships among serum B lymphocyte stimulator levels, autoantibody profile and clinical response. Ann Rheum Dis67: 1011-1016.
20.
Cambridge, G., Leandro, M.J., Edwards, J.C.W., Ehrenstein, M.R., Salden, M., Bodman-Smith, M. et al. (2003) Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis. Arthritis Rheum48: 2146-2154.
21.
Chan, T.M., Li, F.K., Tang, C.S., Wong, R.W., Fang, G.X., Ji, Y.L. et al. (2000) Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group. N Engl J Med343: 1156-1162.
22.
Chan, T.-M., Tse, K.-C., Tang, C.S.-O., Mok, M.-Y. and Li, F.-K. ( 2005) Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis . J Am Soc Nephrol16: 1076-1084.
23.
Chung, C.P., Avalos, I., Oeser, A., Gebretsadik, T., Shintani, A., Raggi, P. et al. (2006) High prevalence of the metabolic syndrome in patients with systemic lupus erythematosus: association with disease characteristics and cardiovascular risk factors. Ann Rheum Dis66: 208-214.
24.
Contreras, G., Pardo, V., Leclercq, B., Lenz, O., Tozman, E., O’Nan, P. et al. (2004) Sequential therapies for proliferative lupus nephritis. N Engl J Med350: 971-980.
25.
Cunnane, G., Chan, O.T.M., Cassafer, G., Brindis, S., Kaufman, E., Yen, T.S.B. et al. (2004) Prevention of renal damage in murine lupus nephritis by CTLA-4Ig and cyclophosphamide. Arthritis Rheum50: 1539-1548.
26.
D’Cruz, D. ( 2001) Antimalarial therapy: a panacea for mild lupus?Lupus10: 148-151.
27.
D’Cruz, D., Tanasescu, C., Navarra, S., Guzman, R., Gallacher, A., Levy, R. et al. (2010) Belimumab, a BLYSspecific inhibitor, reduced disease activity, flares and prednisone use in patients with active seropositive SLE: Phase 3 BLISS-52 study. Rheumatology49(Suppl. 1): i2.
28.
Dall’Era, M., Chakravarty, E., Wallace, D., Genovese, M., Weisman, M., Kavanaugh, A. et al. (2007) Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating trial. Arthritis and Rheumatism56: 4142-4150.
29.
Ding, C. and Jones, G. ( 2006) Belimumab Human Genome Sciences/Cambridge Antibody Technology/ GlaxoSmithKline. Current Opin Investigational Drugs7: 464-472.
30.
Dörner, T., Kaufmann, J., Wegener, W.A., Teoh, N., Goldenberg, D.M. and Burmester, G.R. ( 2006) Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus. Arthritis Res Therapy8: R74.
31.
Edwards, J.C.W., Szczepanski, L., Szechinski, J., Filipowicz-Sosnowska, A., Emery, P., Close, D.R. et al. (2004) Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med350: 2572-2581.
32.
Esdaile, J.M., Abrahamowicz, M., Grodzicky, T., Li, Y., Panaritis, C., du Berger, R. et al. (2001) Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus . Arthritis Rheum44: 2331-2337.
33.
Fessler, B.J., Alarcón, G.S., McGwin, G., Roseman, J., Bastian, H.M. and Friedman, A.W. ( 2005) Systemic lupus erythematosus in three ethnic groups: XVI. Association of hydroxychloroquine use with reduced risk of damage accrual . Arthritis Rheum52: 1473-1480.
34.
Flanc, R.S., Roberts, M.A., Strippoli, G.F.M., Chadban, S.J., Kerr, P.G. and Atkins, R.C. ( 2004) Treatment of diffuse proliferative lupus nephritis: a meta-analysis of randomized controlled trials. Am J Kidney Dis43: 197-208.
35.
Fortin, P.R., Abrahamowicz, M., Ferland, D., Lacaille, D., Smith, C.D. and Zummer, M. ( 2008) Steroid-sparing effects of methotrexate in systemic lupus erythematosus: a double-blind, randomized, placebo-controlled trial. Arthritis Rheum59: 1796-1804.
36.
Gatto, B. ( 2008) Atacicept, a homodimeric fusion protein for the potential treatment of diseases triggered by plasma cells. Current Opin Investigational Drugs9: 1216-1227.
37.
Ginzler, E.M., Dooley, M.A., Aranow, C., Kim, M.Y., Buyon, J., Merrill, J.T. et al. (2005) Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med353: 2219-2228.
38.
Ginzler, E.M., Wofsy, D., Isenberg, D., Gordon, C., Lisk, L., Dooley, M.-A. and ALMS Group (2010) Nonrenal disease activity following mycophenolate mofetil or intravenous cyclophosphamide as induction treatment for lupus nephritis: Findings in a multicenter, prospective, randomized, open-label, parallel-group clinical trial. Arthritis Rheum62: 211-221.
39.
Gladman, D.D., Goldsmith, C.H., Urowitz, M.B., Bacon, P., Fortin, P., Ginzler, E. et al. (2000) The Systemic Lupus International Collaborating Clinics/ American College of Rheumatology (SLICC/ACR) Damage Index for systemic lupus erythematosus international comparison. J Rheumatol27: 373-376.
40.
GlaxoSmithKline (2009) GlaxoSmithKline and Human Genome Sciences announce positive results in second of two phase 3 trials of Benlysta in systemic lupus erythematosus. http://www.gsk.com/media/pressreleases/2009/2009_pressrelease_10121.htm
41.
Gourley, M.F., Austin, H.A., Scott, D., Yarboro, C.H., Vaughan, E.M., Muir, J. et al. (1996) Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. A randomized, controlled trial. Ann Internal Med125: 549-557.
42.
Griffiths, B. and Emery, P. ( 2001) The treatment of lupus with cyclosporin A. Lupus10: 165-170.
43.
Griffiths, B., Emery, P., Ryan, V., Isenberg, D., Akil, M., Thompson, R. et al. (2010) The BILAG multi-centre open randomized controlled trial comparing ciclosporin vs azathioprine in patients with severe SLE. Rheumatology, doi:10.1093/rheumatology/kep396.
44.
Gunnarsson, I., Sundelin, B., Jónsdóttir, T., Jacobson, S.H., Henriksson, E.W. and van Vollenhoven, R.F. ( 2007) Histopathologic and clinical outcome of rituximab treatment in patients with cyclophosphamide-resistant proliferative lupus nephritis . Arthritis Rheum56: 1263-1272.
Herishanu, Y. ( 2002) Rituximab-induced serum sickness. Am J Hematol70: 329.
47.
Houssiau, F.A., Vasconcelos, C., D’Cruz, D., Sebastiani, G.D., de Ramon Garrido, E., Danieli, M.G. et al. (2010) The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide . Ann Rheum Dis69: 61-64.
48.
Illei, G.G., Austin, H.A., Crane, M., Collins, L., Gourley, M.F., Yarboro, C.H. et al. (2001) Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis. Ann Internal Med135: 248-257.
49.
Johnson, A.E., Gordon, C., Palmer, R.G. and Bacon, P.A. ( 1995) The prevalence and incidence of systemic lupus erythematosus in Birmingham, UK, related to ethnicity and country of birth. Arthritis Rheum38: 551-558.
50.
Jonsson, H., Nived, O., Sturfelt, G. and Silman, A. ( 1990) Estimating the incidence of systemic lupus erythematosus in a defined population using multiple sources of retrieval. Br J Rheumatolol29: 185-188.
51.
Kalled, S.L. ( 2005) The role of BAFF in immune function and implications for autoimmunity. Immunol Rev204: 43-54.
52.
Kalunian, K.C., Davis, J.C., Merrill, J.T., Totoritis, M.C. and Wofsy, D. ( 2002) Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti-CD154: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum46: 3251-3258.
53.
Kremer, J.M., Westhovens, R., Leon, M., Di Giorgio, E., Alten, R., Steinfeld, S. et al. (2003) Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N Engl J Med349: 1907-1915.
54.
Lander, S.A., Wallace, D.J. and Weisman, M.H. ( 2002) Celecoxib for systemic lupus erythematosus: case series and literature review of the use of NSAIDs in SLE. Lupus11(6): 340-347.
55.
Leandro, M.J., Cambridge, G., Edwards, J.C., Ehrenstein, M.R. and Isenberg, D.A. ( 2005) B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients. Rheumatology (Oxford) 44: 1542-1545.
56.
Leong, K.H., Koh, E.T., Feng, P.H. and Boey, M.L. ( 1994) Lipid profiles in patients with systemic lupus erythematosus . J Rheumatol21: 1264-1267.
57.
Levy, M., Buskila, D., Gladman, D.D., Urowitz, M.B. and Koren, G. ( 1991) Pregnancy outcome following first trimester exposure to chloroquine. Am J Perinatol8: 174-178.
58.
Liossis, S.-N.C. and Sfikakis, P.P. ( 2004) Costimulation blockade in the treatment of rheumatic diseases . BioDrugs: Clin Immunotherapeut Biopharm Gene Therapy18: 95-102.
59.
Looney, R.J., Anolik, J.H., Campbell, D., Felgar, R.E., Young, F., Arend, L.J. et al. (2004) B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab. Arthritis Rheum50: 2580-2589.
60.
Lu, T.Y.-T., Ng, K.P., Cambridge, G., Leandro, M.J., Edwards, J.C.W., Ehrenstein, M. et al. (2009) A retrospective seven-year analysis of the use of B cell depletion therapy in systemic lupus erythematosus at University College London Hospital: the first fifty patients. Arthritis Rheum61: 482-487.
61.
Manzi, S., Meilahn, E.N., Rairie, J.E., Conte, C.G., Medsger, T.A., Jansen-McWilliams, L. et al. (1997) Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. Am J Epidemiol145: 408-415.
62.
Merrill, J.T., Burgos-Vargas, R., Chalmers, A., D’Cruz, D., Bae, S.C., Sigal, L. et al. (2008) The efficacy and safety of abatacept in SLE: results of a 12-month exploratory study. Arthritis Rheum57: L13.
63.
Merrill, J.T., Neuwelt, C.M., Wallace, D.J., Shanahan, J.C., Latinis, K.M., Oates, J.C. et al. (2010) Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum62: 222-233.
64.
Mok, C.C. ( 2007) Mycophenolate mofetil for nonrenal manifestations of systemic lupus erythematosus: a systematic review. Scand J Rheumatol36: 329-337.
65.
Mok, C.C. and Lau, C.S. ( 2003) Pathogenesis of systemic lupus erythematosus. Br Med J56: 481-490.
66.
Mok, C.C., Ying, K.Y., Tang, S., Leung, C.Y., Lee, K.W., Ng, W.L. et al. (2004) Predictors and outcome of renal flares after successful cyclophosphamide treatment for diffuse proliferative lupus glomerulonephritis . Arthritis Rheum50: 2559-2568.
67.
Mosca, M., Tani, C., Aringer, M., Bombardieri, S., Boumpas, D., Brey, R. et al. (2008) EULAR recommendations for monitoring systemic lupus erythematosus patients in clinical practice and in observational studies . Ann Rheum Dis67: 195-205.
68.
Ng, K.P., Cambridge, G., Leandro, M.J., Edwards, J.C.W., Ehrenstein, M. and Isenberg, D.A. ( 2007) B cell depletion therapy in systemic lupus erythematosus: long-term follow-up and predictors of response. Ann Rheum Dis66: 1259-1262.
69.
stensen, M., Khamashta, M., Lockshin, M., Parke, A., Brucato, A., Carp, H. et al. (2006) Anti-inflammatory and immunosuppressive drugs and reproduction. Arthritis Res Therapy8: 209.
70.
stensen, M., Lockshin, M., Doria, A., Valesini, G., Meroni, P., Gordon, C. et al. (2008) Update on safety during pregnancy of biological agents and some immunosuppressive anti-rheumatic drugs. Rheumatology (Oxford) 47(Suppl. 3): iii28-31.
71.
stensen, M. and Villiger, P.M. ( 2001) Nonsteroidal anti-inflammatory drugs in systemic lupus erythematosus. Lupus10: 135-139.
72.
Parke, A. and West, B. ( 1996) Hydroxychloroquine in pregnant patients with systemic lupus erythematosus. J Rheumatol23: 1715-1718.
73.
Petri, M., Hobbs, K., Gordon, C., Straaton, V., Wallace, D., Kelly, L. et al. (2008) Clinically meaningful improvements with Epratuzumab (Anti-CD22 mAb targeting B-cells) in patients with moderate/severe SLE flares: Results from 2 randomized controlled trials. Arthritis Rheum57: 1087.
74.
Petri, M., Lakatta, C., Magder, L. and Goldman, D. ( 1994) Effect of prednisolone and hydroxychloroquine on coronary artery disease risk factors in systemic lupus erythematosus: a longitudinal data analysis. Am J Med96: 254-259.
75.
Pons-Estel, G.J., Alarcón, G.S., Scofield, L., Reinlib, L. and Cooper, G.S.(2010) Understanding the epidemiology and progression of systemic lupus erythematosus . Semin Arthritis Rheum39: 257-268.
76.
Radis, C.D., Kahl, L.E., Baker, G.L., Wasko, M.C., Cash, J.M., Gallatin, A. et al. (1995) Effects of cyclophosphamide on the development of malignancy and on long-term survival of patients with rheumatoid arthritis. A 20-year followup study. Arthritis Rheum38: 1120-1127.
77.
Rahman, P., Gladman, D.D., Urowitz, M.B., Yuen, K., Hallett, D. and Bruce, I.N. ( 1999) The cholesterol lowering effect of antimalarial drugs is enhanced in patients with lupus taking corticosteroid drugs. J Rheumatol26: 325-330.
78.
Ramos-Casals, M., Soto, M.J., Cuadrado, M.J. and Khamashta, M.A.(2009) Rituximab in systemic lupus erythematosus: a systematic review of off-label use in 188 cases. Lupus18: 767-776.
79.
Reff, M.E., Carner, K., Chambers, K.S., Chinn, P.C., Leonard, J.E., Raab, R. et al. (1994) Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood83: 435-445.
80.
Remer, C.F., Weisman, M.H. and Wallace, D.J. ( 2001) Benefits of leflunomide in systemic lupus erythematosus: a pilot observational study. Lupus10: 480-483.
81.
Reuters (2009) UCB and Immunomedics Announce Positive Results for Epratuzumab Phase IIb Study in Systemic Lupus Erythematosus (SLE), Reuters, http://www.reuters.com/article/idUS59586+27-Aug-2009+GNW20090827.
82.
Roman, M.J., Shanker, B.-A., Davis, A., Lockshin, M.D., Sammaritano, L., Simantov, R. et al. (2003) Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med349: 2399-2406.
83.
Royal College of Ophthalmologists, The British Society of Rheumatology and British Association of Dermatologists (2009) Hydroxychloroquine and Ocular Toxicity: Recommendations on Screening (Replacing the Royal College of Ophthalmologists Guidelines for Screening 2004 and 1998) . London: Royal College of Ophthalmologists, The British Society of Rheumatology and British Association of Dermatologists .
84.
Ruiz-Irastorza, G., Ramos-Casals, M., Brito-Zeron, P. and Khamashta, M.A.(2010) Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. Ann Rheum Dis69: 20-28.
85.
Sfikakis, P.P., Boletis, J.N., Lionaki, S., Vigklis, V., Fragiadaki, K.G., Iniotaki, A. et al. (2005) Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open-label trial. Arthritis Rheum52: 501-513.
86.
Smith, K.G.C., Jones, R.B., Burns, S.M. and Jayne, D.R.W. ( 2006) Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: Remission, relapse, and re-treatment . Arthritis Rheum54: 2970-2982.
87.
Stillwell, T.J., Benson, R.C., DeRemee, R.A., McDonald, T.J. and Weiland, L.H. ( 1988) Cyclophosphamide-induced bladder toxicity in Wegener’s granulomatosis. Arthritis Rheum31: 465-470.
88.
Strand, V., Gordon, C., Kalunian, K., Coteur, G., Barry, A., Keininger, G. et al. (2008) Meaningful improvements in Health Related Quality of Life (HRQOL) with Epratuzumab (anti-CD22 mAb targeting B cells) shown in patients with SLE with high disease activity: Results from 2 randomized controlled trials (RCTs). Arthritis Rheum58: 1086.
89.
Tam, L.-S., Li, E.K., Wong, C.-K., Lam, C.W.K. and Szeto, C.-C. ( 2004) Double-blind, randomized, placebo-controlled pilot study of leflunomide in systemic lupus erythematosus. Lupus13: 601-604.
90.
Tew, G.W., Rabbee, N., Wolslegel, K., Hsieh, H.-J., Monroe, J.G., Behrens, T.W. et al. (2010) Baseline autoantibody profiles predict normalization of complement and anti-dsDNA autoantibody levels following Rituximab treatment in systemic lupus erythematosus. Lupus19: 146-157.
91.
Tokunaga, M., Saito, K., Kawabata, D., Imura, Y., Fujii, T., Nakayamada, S. et al. (2007) Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system. Ann Rheum Dis66: 470-475.
92.
Tseng, C.-E., Buyon, J.P., Kim, M., Belmont, H.M., Mackay, M., Diamond, B. et al. (2006) The effect of moderate-dose corticosteroids in preventing severe flares in patients with serologically active, but clinically stable, systemic lupus erythematosus: findings of a prospective, randomized, double-blind, placebo-controlled trial. Arthritis Rheum54: 3623-3632.
93.
Urowitz, M.B., Bookman, A.A., Koehler, B.E., Gordon, D.A., Smythe, H.A. and Ogryzlo, M.A. ( 1976) The bimodal mortality pattern of systemic lupus erythematosus . Am J Med60: 221-225.
94.
Wallace, D.J., Stohl, W., Furie, R.A., Lisse, J.R., McKay, J.D., Merrill, J.T. et al. (2009) A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus . Arthritis Rheum61: 1168-1178.
95.
Wallace, D.J., Metzger, A.L., Stecher, V.J., Turnbull, B.A. and Kern, P.A. ( 1990) Cholesterol-lowering effect of hydroxychloroquine in patients with rheumatic disease: reversal of deleterious effects of steroids on lipids . Am J Med89: 322-326.
96.
Wong, J.M. and Esdaile, J.M. ( 2005) Methotrexate in systemic lupus erythematosus. Lupus14: 101-105.
